Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tam Dang-Tan

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Cancer|July 11, 2007
Diagnosis delays in childhood cancer: a reviewTam Dang-Tan, Eduardo L Franco
Patient Education and Counseling|March 5, 2004
Self-management and behaviour modification in COPD Jean Bourbeau, Diane Nault, Tam Dang-Tan
Oncogene|August 24, 2004
Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal associationTam Dang-Tan, Salaheddin M Mahmud, Riccardo Puntoni, et al.
BMC Research Notes|September 23, 2015
Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic reviewTam Dang-Tan, Afisi Ismaila, Shiyuan Zhang, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 11, 2018
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 YearsQian Li, Rahul Ganguly, Michael L Ganz, et al.
Advances in Therapy|January 12, 2020
Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United StatesSarah Naz Ali, Tam Dang-Tan, William J Valentine, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 16, 2020
Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical AnalysisMoshe Fridman, Mariann E Lucas, Yurek Paprocki, et al.
Advances in Therapy|March 16, 2019
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Advances in Therapy|April 14, 2019
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Clinical Therapeutics|March 31, 2021
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage PopulationJay Visaria, Chioma Uzoigwe, Caroline Swift, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Cancer|July 11, 2007
Diagnosis delays in childhood cancer: a reviewTam Dang-Tan, Eduardo L Franco
Patient Education and Counseling|March 5, 2004
Self-management and behaviour modification in COPD Jean Bourbeau, Diane Nault, Tam Dang-Tan
Oncogene|August 24, 2004
Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal associationTam Dang-Tan, Salaheddin M Mahmud, Riccardo Puntoni, et al.
BMC Research Notes|September 23, 2015
Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic reviewTam Dang-Tan, Afisi Ismaila, Shiyuan Zhang, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 11, 2018
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 YearsQian Li, Rahul Ganguly, Michael L Ganz, et al.
Advances in Therapy|January 12, 2020
Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United StatesSarah Naz Ali, Tam Dang-Tan, William J Valentine, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 16, 2020
Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical AnalysisMoshe Fridman, Mariann E Lucas, Yurek Paprocki, et al.
Advances in Therapy|March 16, 2019
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Advances in Therapy|April 14, 2019
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAPierre Johansen, Barnaby Hunt, Neeraj N Iyer, et al.
Clinical Therapeutics|March 31, 2021
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage PopulationJay Visaria, Chioma Uzoigwe, Caroline Swift, et al.
Pageof 3